Biosearch starts antibiotic trial
Italian company Biosearch is starting a Phase II trial on its investigational glycopeptide antibiotic dalbavancin (formerly BI-397) for the treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria, notably Staphylococcus species. The randomised, controlled, open-label trial will be carried out by its US licensee Versicor on hospitalised patients with infections such as burns, abcesses or infected ulcers.